Axatilimab (CSF1R monoclonal antibody)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-15 — Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML): Phase I/II trial (trial-early) evaluating axatilimab as monotherapy and in combination with ruxolitinib in MF and CMML to establish recommended dosing and preliminary disease-control activity — first clinical test of CSF1R blockade (macrophage/monocyte-directed) added to a JAK1/2 backbone in these populations; abstract is dose-finding/objectives only with no efficacy or mechanistic results yet. (novelty: 3)
Open questions
Related
Contributing findings
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
15-jul-2026
novelty 3
per-area 4
introduces